^
Association details:
| Biomarker: | PIK3CA H1047R + HER-2 amplification |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + rupitasertib (DIACC3010) (AKT inhibitor, p70S6K inhibitor, AKT1 inhibitor, AKT3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer
Published date:
08/18/2021
Excerpt:
...a 66-year-old woman with triple-positive breast cancer, previously treated with four lines of therapy....Pretreatment tumor molecular profiling identified multiple alterations including ERBB2 amplification and PIK3CA H1047R mutation. She was treated with 160 mg M2698 combined with trastuzumab and tamoxifen (20 mg daily) (per protocol for triple-positive disease). The duration of PFS was 31 months (see Additional file 1).
Secondary therapy:
tamoxifen
DOI:
10.1186/s13045-021-01132-z
Trial ID:
